CD19 and neoplasm: Furthermore, CAR-CD19 T cells treated mice showed a reduction in the tumor burden and increased survival rate compared to mocked cells treated mice at all dose levels, suggesting that the current doses provide a beneficial effect in mice with human CD19-positive tumors.